Additional file 1 of Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Creators: name: Barbosa, Alexandre Naime
name: Chebabo, Alberto
name: Starling, Carlos
name: Pérez, Clevy
name: Cunha, Clóvis Arns
name: de Luna, David
name: Nunes, Estevão Portela
name: Zambrano, Gabriela
name: Ferreira, Juliana Carvalho
name: Croda, Julio
name: Falavigna, Maicon
name: Gomes-da-Silva, Monica Maria
name: Thormann, Monica
name: Cimerman, Sergio
name: Parahiba, Suena Medeiros
name: Tanni, Suzana
name: Bernardo, Wanderley Marques
name: Rodriguez-Morales, Alfonso J.
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1: The additional material includes information on the construction process of these guidelines, as well as the results of the synthesis and evaluation of the evidence. Table S1. Search strategies for systematic reviews. Table S2. Disclosure of financial interests for panel members involved on recommendations. Table S3. Should Tixagevimab + Cilgavimab treatment be recommended for pre-exposure prophylaxis in people at high risk of developing severe COVID-19?. Table S4. Should monoclonal antibody (Tixagevimab + Cilgavimab) treatment be recommended for outpatients with mild COVID-19?a. Table S5. Should molnupiravir treatment be recommended for outpatients with mild COVID-19 without risk factors for severe disease?. Table S6. Should molnupiravir treatment be recommended for outpatients with mild COVID-19 with risk factors for severe disease?. Table S7. Should Nirmatrelvir/ ritonarir treatment be recommended for outpatients with mild COVID-19?. Table S8. Should Remdesivir treatment be recommend for outpatients with mild COVID-19?. Table S9. Should Hidroxychloroquine treatment be recommended for outpatients with mild COVID-19?. Table S10. Should Ivermectin treatment be recommended for outpatients with mild COVID-19?. Table S11. Should Remdesivir treatment be recommended for hospitalized patients with severe COVID-19?. Table S12. Should Baracitinib treatment be recommended for hospitalized patients with severe COVID-19?. Table S13. Should Baracitinib treatment vs. dexamethasone be recommended for hospitalized patients with severe COVID-19?. Table S14. Should Tocilizumab treatment be recommended for hospitalized patients with severe COVID-19?. Table S15. Evidence to decision framework for recommending Tixagevimab + Cilgavimab treatment of pre-exposure prophylaxis in people at high risk of developing COVID-19. Table S16. Evidence to decision framework for recommending Tixagevimab + Cilgavimab treatment in outpatients with mild COVID-19. Table S17. Evidence to decision framework for recommending Molnupiravir treatment in outpatients with mild COVID-19. Table S18. Evidence to decision framework for recommending Nirmatrevir/Ritonavir treatment in outpatients with mild COVID-19. Table S19. Evidence to decision framework for recommending Remdesivir treatment in outpatients with mild COVID-19. Table S20. Evidence to decision framework for recommending Hidroxychloroquine or Chloroquine treatment in outpatients with mild COVID-19. Table S21. Evidence to decision framework for recommending Ivermectin treatment in outpatients with mild COVID-19. Table S22. Evidence to decision framework for recommending Remdesivir treatment in hospitalized patients with severe COVID-19. Table S23. Evidence to decision framework for recommending Baricitinib treatment in hospitalized patients with severe COVID-19. Table S24. Evidence to decision framework for recommending Tocilizumab treatment in hospitalized patients with severe COVID-19. Figure S1. Flow chart of study selection of Tixagevimab and Cilgavimab in Covid-19 pre-exposure prophylaxis. Figure S2. Flow chart of study selection of monoclonal antibody in outpatients with mild COVID-19. Figure S3. Flow chart of study selection of Nirmatrelvir plus Ritonavir in outpatients with mild COVID-19. Figure S4. Flow chart of study selection of Molnupiravir in outpatients with mild COVID-19. Figure S5. Flow chart of study selection of Remdesivir in outpatients with mild COVID-19. Figure S6. Flow chart of study selection of Hidroxychloroquine and Chloroquine in outpatients mild COVID-19. Figure S7. Flow chart of study selection of Ivermectin in outpatients mild COVID-19. Figure S8. Flow chart of study selection of Rendesivir in hospitalized patients with severe COVID-19. Figure S9. Flow chart of study selection of Baracitinib in hospitalized patients with severe COVID-19. Figure S10. Flow chart of study selection of Tocilizumab in hospitalized patients with severe COVID-19. Figure S11. Effect of Molnupiravir compared to control on mortality of outpatients with mild COVID-19. Figure S12. Effect of Molnupiravir compared to control on hospitalization of outpatients with mild COVID-19. Figure S13. Effect of Molnupiravir compared to control on serious adverse events in outpatients with mild COVID-19. Figure S14. Effect of Hidroxychloroquine and Chloroquine compared to control on mortality of outpatients with mild COVID-19. Figure S15. Effect of Hidroxychloroquine and Chloroquine compared to control on hospitalization of outpatients with mild COVID-19. Figure S16. Effect of Hidroxychloroquine and Chloroquine compared to control on serious adverse events in outpatients with mild COVID-19. Figure S17. Effect of Ivermectin compared to control on hospitalization of outpatients with mild COVID-19. Figure S18. Effect of Ivermectin compared to control on serious adverse events in outpatients with mild COVID-19. Figure S19. Effect of Remdesivir compared to control on mortality of hospitalized patients with severe COVID-19. Figure S20. Effect of Remdesivir compared to control on mechanical ventilation of hospitalized patients with severe COVID-19. Figure S21. Effect of Remdesivir compared to control on serious adverse events in hospitalized patients with severe COVID-19. Figure S22. Effect of Tocilizumab compared to control on mortality in hospitalized patients with severe COVID-19. Figure S23. Effect of Tocilizumab compared to control on mechanical ventilation in hospitalized patients with severe COVID-19. Figure S24. Effect of Tocilizumab compared to control on serious adverse events in hospitalized patients with severe COVID-19. Figure S25. Risk of bias assessment for the study of Tixagevimab + Cilgavimab in COVID-19 pre-exposure prophylaxis. Figure S26. Risk of bias assessment for the study of Tixagevimab + Cilgavimab in outpatients with mild COVID-19. Figure S27. Risk of bias assessment for the studies of Molnupiravir in outpatients with mild COVID-19. Figure S28. Risk of bias assessment for the study of Remdesivir in outpatients with mild COVID-19. Figure S29. Risk of bias assessment for the study of Nirmatrelvir plus Ritonavir in outpatients with mild COVID-19. Figure S30. Risk of bias assessment for the studies of Hidroxychloroquine and Chloroquine in outpatients with mild COVID-19. Figure S31. Risk of bias assessment for the studies of Ivermectin in outpatients with mild COVID-19. Figure S32. Risk of bias assessment for the study of Baricitinib in hospitalized patients with severe COVID-19. Figure S33. Risk of bias assessment for the studies of Tocilizumab in hospitalized patients with severe COVID-19.